On March 26, 2026, Microbot Medical Inc. (NASDAQ: MBOT) issued a joint press release with Emory Healthcare, highlighting the successful completion of robotic peripheral endovascular procedures utilizing the company's LIBERTY™ Endovascular Robotic System. This innovative system has been employed in minimally invasive treatments for various vascular conditions, including benign prostatic hyperplasia (BPH) and liver cancer. Emory interventional radiologists have successfully demonstrated the use of the LIBERTY System for the world's first robotic Prostatic Artery Embolization (PAE) for BPH, showcasing the system's versatility and effectiveness in treating complex medical conditions. The LIBERTY System is designed to enhance precision in vascular navigation while reducing radiation exposure and physical strain on clinicians. The successful implementation of these procedures at Emory Healthcare is expected to bolster Microbot Medical's market position and drive further adoption of its robotic technology in the medical field. Harel Gadot, Chairman and CEO of Microbot Medical, expressed confidence in the system's potential to establish endovascular robotic navigation as a standard of care for PAE, similar to the widespread adoption of robotic-assisted prostatectomy for prostate cancer treatment. The company plans to showcase the LIBERTY System at the upcoming Society of Interventional Radiology conference in April 2026, aiming to deepen market adoption and expand patient access to high-quality care.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.